Auris Nasus Larynx
Volume 34, Issue 4 , Pages 493-498, December 2007

Surgical treatment versus concurrent chemoradiotherapy as an initial treatment modality in advanced olfactory neuroblastoma

  • Hyun Jik Kim

      Affiliations

    • Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, Chung-Ang University, Republic of Korea
    • ,
  • Chang-Hoon Kim

      Affiliations

    • Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea
    • ,
  • Bong-Jae Lee

      Affiliations

    • Department of Otolaryngology, Asan Medical Center, College of Medicine, University of Ulsan, Republic of Korea
    • ,
  • Yoo-Sam Chung

      Affiliations

    • Department of Otolaryngology, Asan Medical Center, College of Medicine, University of Ulsan, Republic of Korea
    • ,
  • Jin Kook Kim

      Affiliations

    • Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, Konkuk University, Seoul, Republic of Korea
    • ,
  • Yoon-Seok Choi

      Affiliations

    • Department of Otorhinolaryngology-Head and Neck Surgery, Inha University College of Medicine, Incheon, Republic of Korea
    • ,
  • Joo-Heon Yoon

      Affiliations

    • Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea
    • Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, Seoul, Republic of Korea
    • Corresponding Author InformationCorresponding author at: Department of Otorhinolaryngology, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, Republic of Korea. Tel.: +82 2 2228 3610; fax: +82 2 393 0580.

Received 11 December 2006; accepted 18 February 2007.

Abstract 

Objective

Olfactory neuroblastomas are very aggressive tumors with a high locoregional recurrence rate and distant metastasis. Surgical treatment, including craniofacial resection, has been the main treatment modality, but treatment outcomes of concurrent chemoradiotherapy remain unclear. We present our experiences regarding the treatment outcome of patients with advanced olfactory neuroblastoma undergoing surgical treatment and concurrent chemoradiotherapy.

Methods

We retrospectively analyzed 16 patients treated for advanced olfactory neuroblastoma within the past 10 years.

Results

The disease-free 5-year survival rate of the patients (n=10) who underwent surgical treatment was 68%. The survival rate for patients (n=6) who received concurrent chemoradiotherapy was 42%. The difference in the survival rate was not statistically significant, and no difference in the recurrence rate between the two groups. In the group having surgical treatment, post-operative radiotherapy and salvage therapy were important to increase the survival rate. In the group having concurrent chemoradiotherapy, no patient experienced primary tumor progression.

Conclusion

Complete surgical resection, including craniofacial resection (CFR), and post-operative radiotherapy seem to be essential in the treatment of advanced olfactory neuroblastoma. However, concurrent chemoradiotherapy may be another primary treatment modality.

Keywords: Olfactory neuroblastoma, Craniofacial resection, Concurrent chemoradiotherapy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0385-8146(07)00055-7

doi:10.1016/j.anl.2007.02.005

Auris Nasus Larynx
Volume 34, Issue 4 , Pages 493-498, December 2007

Article Tools

* Image Usage & Resolution